Company Profile
Clover Biopharmaceuticals, Ltd., a biotechnology company provides the research and development, manufacture, and commercialization of vaccines in Mainland China and globally. The company's product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine.
Its portfolio also includes AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza, and SCB-219M, a thrombocytopenia receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia.
It is also developing SCB-2023B for COVID-19 treatment. Its portfolio also includes SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets, and SCB-1001 for rabies treatment. Additionally, it sells biopharmaceutical drugs. Founded in 2007, the company is headquartered in Shanghai, the People's Republic of China.